BeyondSpring Inc. announced that the China Food and Drug Administration (CFDA) has approved the Company’s Clinical Trial Applications (CTAs) to allow the initiation of two global Phase 2/3 trials for its innovative lead asset, Plinabulin, for the prevention of chemotherapy-induced neutropenia in China. This is the second global registration trial for Plinabulin in addition to the Phase 3 non-small cell lung cancer (NSCLC) trial. Dr. Shi is the Vice Chairman of the Cancer Hospital Chinese Academy of Medical Sciences in Beijing, which treats over 370,000 cancer patients a year. He has been instrumental in developing G-CSF products, the current standard of care for chemotherapy-induced neutropenia, for the China market. Plinabulin is a novel small molecule with immune-enhancing effects and anti-cancer activity that is administered by IV infusion – one hour after chemotherapy – and has the potential to be a safe, cost-effective and convenient alternative to G-CSF, with less bone pain and a more favorable safety profile. Plinabulin offers a same-day dosing advantage over G-CSF, which, per product label, should be administered 24 hours after chemotherapy (next-day dosing), by which time a significant insult to neutrophil production has occurred. Plinabulin has also demonstrated a reduction in the clinical sequelae associated with docetaxel-induced neutropenia – i.e., infections, sepsis, hospitalizations and the need for docetaxel dose reductions.